Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTCY NASDAQ:FEMY NASDAQ:ICCM NASDAQ:OSRH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTCYBiotricity$0.13+4.3%$0.15$0.10▼$0.75$3.72M1.1460,279 shs311 shsFEMYFemasys$3.99+3.6%$5.93$3.50▼$22.20$12.05M-2.1341,438 shs27,062 shsICCMIceCure Medical$3.65-6.2%$5.70$2.12▼$42.00$12.51M0.4310.15 million shs125,819 shsOSRHOSR$0.33-0.2%$0.44$0.30▼$1.27$11.53M0.72563,125 shs196,501 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTCYBiotricity+4.34%-7.08%+18.09%-47.02%-66.43%FEMYFemasys+3.64%-4.32%-15.64%-49.75%-79.43%ICCMIceCure Medical-6.17%-31.90%+43.70%-62.37%-88.52%OSRHOSR-0.18%+2.43%-21.36%-38.62%-73.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTCYBiotricity$0.13+4.3%$0.15$0.10▼$0.75$3.72M1.1460,279 shs311 shsFEMYFemasys$3.99+3.6%$5.93$3.50▼$22.20$12.05M-2.1341,438 shs27,062 shsICCMIceCure Medical$3.65-6.2%$5.70$2.12▼$42.00$12.51M0.4310.15 million shs125,819 shsOSRHOSR$0.33-0.2%$0.44$0.30▼$1.27$11.53M0.72563,125 shs196,501 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTCYBiotricity+4.34%-7.08%+18.09%-47.02%-66.43%FEMYFemasys+3.64%-4.32%-15.64%-49.75%-79.43%ICCMIceCure Medical-6.17%-31.90%+43.70%-62.37%-88.52%OSRHOSR-0.18%+2.43%-21.36%-38.62%-73.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTCYBiotricity 0.00N/AN/AN/AFEMYFemasys 2.50Moderate Buy$106.672,573.35% UpsideICCMIceCure Medical 2.40Hold$62.701,617.81% UpsideOSRHOSR 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest BTCY, ICCM, FEMY, and OSRH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026OSRHOSR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/3/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026ICCMIceCure Medical Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$90.00 ➝ $30.005/4/2026ICCMIceCure Medical Alliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/1/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026ICCMIceCure Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTCYBiotricity$12.06M0.31N/AN/A($1.30) per share-0.10FEMYFemasys$2.29M5.26N/AN/A$2.01 per share1.99ICCMIceCure Medical$3.38M3.70N/AN/A$3.72 per share0.98OSRHOSR$2.91M3.96N/AN/A$4.95 per share0.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTCYBiotricity-$14.09M-$0.16N/AN/AN/A-80.42%N/A-188.47%7/21/2026 (Estimated)FEMYFemasys-$18.63M-$5.40N/AN/AN/A-521.97%-258.08%-73.72%8/12/2026 (Estimated)ICCMIceCure Medical-$15.06M-$7.21N/AN/AN/A-441.60%-211.73%-119.13%8/12/2026 (Estimated)OSRHOSR-$27.06M-$0.33N/AN/AN/A-363.26%-7.24%-5.41%N/ALatest BTCY, ICCM, FEMY, and OSRH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/21/2026Q4 2026BTCYBiotricity-$0.08N/AN/AN/A$4.10 millionN/A5/13/2026Q1 2026OSRHOSRN/A-$0.09N/A-$0.0880N/A$0.48 million5/12/2026Q1 2026ICCMIceCure Medical-$0.03-$0.06-$0.03$1.80$1.34 million$0.91 million5/8/2026Q1 2026FEMYFemasys-$1.3334$0.0980+$1.4314N/A$0.77 million$0.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTCYBiotricityN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/AICCMIceCure MedicalN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTCYBiotricityN/A0.230.10FEMYFemasys0.533.911.98ICCMIceCure MedicalN/A2.521.97OSRHOSRN/A0.160.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTCYBiotricity3.89%FEMYFemasys65.27%ICCMIceCure Medical0.62%OSRHOSR55.30%Insider OwnershipCompanyInsider OwnershipBTCYBiotricity1.60%FEMYFemasys7.75%ICCMIceCure Medical2.44%OSRHOSR36.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTCYBiotricity4028.60 million22.08 millionNo DataFEMYFemasys303.02 million2.79 millionNot OptionableICCMIceCure Medical603.43 million3.34 millionNot OptionableOSRHOSRN/A35.10 million22.19 millionN/ABTCY, ICCM, FEMY, and OSRH HeadlinesRecent News About These CompaniesOSR Health Earnings Estimates, EPS & Revenue | NASDAQ:OSRHJuly 6, 2026 | benzinga.comAnalyzing OSR (NASDAQ:OSRH) and Marblegate Acquisition (NASDAQ:GATE)July 5, 2026 | americanbankingnews.comCORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price TargetJuly 2, 2026 | finance.yahoo.comEmerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price TargetJuly 2, 2026 | accessnewswire.comAOSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional SharesJune 25, 2026 | accessnewswire.comAOSR Holdings Is Now OSR Health - A New Name That Says Exactly What We DoJune 22, 2026 | accessnewswire.comAOSR Holdings Rebrands as OSR Health in Name ChangeJune 17, 2026 | tipranks.comCEO Statement to ShareholdersJune 3, 2026 | accessnewswire.comAOSR Holdings Secures VXM01 Rights in Asset DealJune 2, 2026 | tipranks.comOSR Holdings, Inc.: OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million TransactionMay 28, 2026 | finanznachrichten.deOSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million TransactionMay 27, 2026 | accessnewswire.comAEmerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price TargetMay 5, 2026 | accessnewswire.comAOSR Holdings, Inc. Common Stock (OSRH) SEC FilingsMay 2, 2026 | nasdaq.comOSRH stock rockets 60% on $815M immunotherapy deal — retail bulls eye $1 mark for the stockApril 30, 2026 | msn.comOSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026April 30, 2026 | accessnewswire.comAOSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM EuropeApril 29, 2026 | accessnewswire.comAOSR Holdings Appoints New COO to Bolster Healthcare FocusApril 22, 2026 | tipranks.comOSR Holdings, Inc.: OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible NoteApril 10, 2026 | finanznachrichten.deOSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible NoteApril 9, 2026 | accessnewswire.comAOSR Holdings Revises Global License Deal for VXM01April 2, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBTCY, ICCM, FEMY, and OSRH Company DescriptionsBiotricity NASDAQ:BTCY$0.13 +0.01 (+4.34%) As of 07/10/2026 12:11 PM EasternBiotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.Femasys NASDAQ:FEMY$3.99 +0.14 (+3.64%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$4.04 +0.05 (+1.28%) As of 07/10/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.IceCure Medical NASDAQ:ICCM$3.65 -0.24 (-6.17%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$3.72 +0.07 (+1.84%) As of 07/10/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.OSR NASDAQ:OSRH$0.33 0.00 (-0.18%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$0.32 0.00 (-1.04%) As of 07/10/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
